text
stringlengths 0
197k
|
|---|
This microscanner can be used ex vivo. In the framework of a project, the learning algorithm was be créated (Convolutional Neural Networks) to automatically segment microscanner slices: after taking FPAS from amputated limbs, we correlated ex-vivo microscanner images of the arteries with their histology. The correlation was then performed manually between the microscanner images, and the histological sections obtained. the algorithm well be trained on these slices and validated its performance. The validation of the CT and microscanner concordance was the subject of scientific publications. conditions: Peripheral Artery Disease conditions: Femoropopliteal Stenosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: Endovascular surgery measure: Assessing the feasibility of histological segmentation of the superficial femoral artery on preoperative microscanner using artificial intelligence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06260475 id: IUA - 246-18 briefTitle: IUA Committee Research Project on the Management of TASC C and D Aortoiliac Lesions overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-31 date: 2024-12-31 date: 2024-02-15 date: 2024-02-15 name: Universidade do Porto class: OTHER name: Clinical Centre of Serbia name: University of Padova name: University of Bari name: University of Trieste name: University of Nis name: Centro Hospitalar de Vila Nova de Gaia/Espinho name: Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro name: Centro Hospitalar do Porto briefSummary: This study aims to evaluate the clinical, imaging results of endovascular revascularization of the aorto-iliac sector in comparison with aortobifemoral bypass and the hybrid approach, in patients with atherosclerotic disease of the iliac sector classified as type C and D by the TransAtlantic Inter-Society Consensus (TASC II conditions: Aortoiliac Atherosclerosis conditions: Aortoiliac Occlusive Disease conditions: Aortoiliac Atherosclerosis With Gangrene conditions: Aortoiliac Atherosclerosis Without Gangrene conditions: Aortoiliac Obstruction conditions: Peripheral Arterial Disease conditions: Peripheral Vascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED name: Aortobifemoral bypass name: aortoiliac stenting measure: Major Amputation measure: Cardiovascular Death measure: acute myorcardial infartion measure: Major Adverse Limb Events measure: Major adverse cardiovascular events measure: Death measure: Intensive care unit instay measure: acute kidney injury (AKI) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centro Hospitalar Universitário de São João, EPE city: Porto zip: 4200-319 country: Portugal name: Joao Rocha-Neves role: CONTACT phone: +351910486230 email: [email protected] lat: 41.14961 lon: -8.61099 facility: Faculdade de Medicina da Universidade do Porto city: Porto zip: 4200-319 country: Portugal lat: 41.14961 lon: -8.61099 hasResults: False |
<|newrecord|> nctId: NCT06260462 id: 10 years adrenal insufficiency briefTitle: Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency overallStatus: COMPLETED date: 2012-01-01 date: 2022-09-30 date: 2023-12-30 date: 2024-02-15 date: 2024-02-15 name: University of Palermo class: OTHER briefSummary: The current study is a randomized, open study aimed to compare the effects of conventional glucocorticoid replacement treatment and dual-release hydrocortisone on anthropometric, metabolic, cardiovascular and bone outcomes in treatment-naïve patients with primary adrenal insufficiency and secondary adrenal insufficiency in a 10 year-observation period. conditions: Adrenal Insufficiency studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 88 type: ACTUAL name: dual-release hydrocortisone name: Conventional glucocortidois measure: Change of body weight measure: Change of anthropometric parameters measure: Change of metabolic parameters measure: Change of insulin sensitivity parameters measure: Change of cardiovascular parameters measure: Change of bone metabolic parameters measure: Change of bone density measure: Change of vascular parameters sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06260449 id: Trematode briefTitle: Different Treatment Approaches of Presumed Trematode-Induced Uveitis overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-21 date: 2024-10-21 date: 2024-12-21 date: 2024-02-15 date: 2024-02-15 name: Assiut University class: OTHER briefSummary: Different Treatment Approaches of Presumed Trematode-Induced Uveitis including periocular injection and medical treatment Nd laser treatment conditions: Uveitis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Single group tested by intervention and medical treatment primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 31 type: ESTIMATED name: Surgical removal measure: Surgical removal sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut city: Assiut country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False |
<|newrecord|> nctId: NCT06260436 id: Tharwat gamal Mohamed briefTitle: Questionnaire of Lower Urinary Tract Symptoms Among Women Before and After Surgical Correction of Uterine Prolapse overallStatus: RECRUITING date: 2021-05-30 date: 2024-09-30 date: 2024-12-30 date: 2024-02-15 date: 2024-02-21 name: Assiut University class: OTHER briefSummary: . The study will include patients who underwent Pelvic reconstructive surgery for advanced pelvic organ prolapse (POP-Q ≥ 3). Data regarding preoperative evaluation, surgical procedure, and post-operative management will be collected. women will receive a follow up questionnaire. . The baseline questionnaire included data on age, urinary incontinence, daytime frequency, nocturia, postmicturition dribble, straining, urgency, incomplete bladder emptying, and hesitancy. Women were asked about leakage caused by coughing or sneezing, moving, lifting, sleeping, sexual intercourse, urgency, and rest. conditions: Pelvic Organ Prolapse studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 180 type: ESTIMATED measure: effect of surgical correction of pelvic organ prolapse on the lower urinary tract symptoms measure: effect of surgical correction of pelvic organ prolapse on the quality of life sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assuit University status: RECRUITING city: Assiut state: Assuit zip: 2063045 country: Egypt name: tharwat gl mohamed role: CONTACT phone: 01151166826 email: [email protected] name: tht tg mohamed role: CONTACT phone: 01017941889 email: [email protected] name: abdelghaffar m mohamed, professor role: PRINCIPAL_INVESTIGATOR lat: 27.18096 lon: 31.18368 hasResults: False |
<|newrecord|> nctId: NCT06260423 id: 18/1/2024 briefTitle: The Effect of Clinical Experience on the Quality of Obturation and Periapical Changes of Teeth Treated With Matched Cones in Combination With Bioceramic Sealer overallStatus: RECRUITING date: 2023-01-01 date: 2025-02-01 date: 2025-04-01 date: 2024-02-15 date: 2024-02-15 name: Al-Azhar University class: OTHER briefSummary: Evaluation of the impact of clinical experience on the quality of obturation and periapical changes of clinical cases using lateral compaction with bioceramic sealers and matched cone obturation with bioceramic sealers both clinically and radiographically. conditions: Obturation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Experienced dentist using lateral compaction with bioceramic sealer. name: Unexperienced dentist using lateral compaction with bioceramic sealer. name: Experienced dentist using Single cone with bioceramic sealer. name: Unexperienced dentist using Single cone with bioceramic sealer. measure: Postoperative pain assessment measure: Postoperative pain assessment measure: Postoperative pain assessment measure: Postoperative pain assessment measure: Postoperative pain assessment measure: The quality of obturation and the voids within the root canal filling sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Al-Azhar university status: RECRUITING city: Cairo zip: 11651 country: Egypt name: Mohamed Badr, Master role: CONTACT phone: 0201111777739 email: [email protected] lat: 30.06263 lon: 31.24967 hasResults: False |
<|newrecord|> nctId: NCT06260410 id: 10512 id: NL84672.078.23 type: OTHER domain: CCMO briefTitle: Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics acronym: LUTRAC overallStatus: RECRUITING date: 2024-02-20 date: 2027-02-01 date: 2027-02-01 date: 2024-02-15 date: 2024-04-22 name: Erasmus Medical Center class: OTHER briefSummary: This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment. conditions: Prostate Cancer Metastatic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Blood draw for ctDNA and circulating tumor cell collection. measure: Overall survival measure: Progression free survival measure: Heterogeneity of PSMA-positivity measure: Effect of CTC PSMA expression on response to treatment. measure: Effect of biomarkers in blood on response to treatment. measure: PSMA-PET scan data and response to treatment. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC status: RECRUITING city: Rotterdam state: Zuid-Holland zip: 3015 CN country: Netherlands name: Stijn Koolen, PhD role: CONTACT phone: +31638740656 email: [email protected] lat: 51.9225 lon: 4.47917 hasResults: False |
<|newrecord|> nctId: NCT06260397 id: analgesia for MRM surgeries briefTitle: Serratus Anterior Plane Block and Costotransverse Block for Analgesia Following Modified Radical Mastectomy Surgeries overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2025-02-28 date: 2025-03-30 date: 2024-02-15 date: 2024-02-26 name: Ain Shams University class: OTHER briefSummary: Adequate pain management following modified radical mastectomy (MRM) is crucial for early ambulation and patient satisfaction. Breast cancer is the most common malignancy in females, with an increasing incidence in recent years. Surgery is one of the mainstays of therapy for breast cancer, and modified radical mastectomy (MRM) is the most effective and common type of invasive surgical treatment. Post-mastectomy pain syndrome (PMPS) is a surgical complication of breast surgery characterized by chronic neuropathic pain. The aim of this study is to investigate the efficacy and safety of single injection CTB versus SAPB on post-operative acute pain as a part of a multimodal analgesia plan in patients undergoing MRM. conditions: Regional Anesthesia Morbidity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: serratus anterior plane block name: costotransverse block name: patient controlled analgesia measure: Visual Analogue Scale score at 0,6,12 and 24 hour post-operatively. visual analogue scale is a scale from 0 to 10, 0 represent no pain at all and 10 represent the worst pain measure: The total dose of nalbuphine consumption is used postoperatively per patient rescue analgesia for 24. sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False |
<|newrecord|> nctId: NCT06260384 id: FMASU R 139/2022 briefTitle: Wolf-Parkinson-White Syndrome and Asymptomatic Pre-excitation in Africa (a Multicenter WPW African Registry) overallStatus: RECRUITING date: 2022-05-01 date: 2024-05-31 date: 2024-10-31 date: 2024-02-15 date: 2024-02-26 name: Ain Shams University class: OTHER briefSummary: The purpose of this prospective observational study is to characterize the clinical profile of patients with WPW syndrome and patients with asymptomatic WPW pattern on ECG in different African countries and how these patients are managed across Africa Participants would include many different ethnicities at centers where the number of cardiac patients treated is high. All patients attending outpatient cardiology clinics or referred to Cath Lab for electrophysiological studies who are diagnosed to have a Wolf-Parkinson white pattern on the ECG are either symptomatic or asymptomatic. All patients fulfilling the eligibility criteria will be approached by the research team and asked if they wish to take part in the study. |
The exclusion criteria will be any participant who does not consent to the study. |
A baseline cardiovascular history (including hypertension, diabetes, heart failure, coronary artery disease, hyperlipidemia, smoking, valve disease, and arrhythmia) will be recorded. |
A detailed history will be taken about symptoms, medications and presence of family history of similar cases or sudden cardiac death 12-lead ECG will be recorded to confirm the presence of pre-excitation and determine the localization of the accessory pathway using the modified Aruda algorithm. This will be done by two of the research teams in each center. |
Then other data from the electrophysiological study and ablation will be filled in by the research team from the data systems of each center. conditions: Wolf Parkinson White Syndrome conditions: Arrythmias studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: electrocardiogram measure: No recurrence of symptoms measure: Assessment of performance outcome of each center sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ain shams university status: RECRUITING city: Cairo state: Outside US zip: 11851 country: Egypt name: Nabil M Farag, MD role: CONTACT phone: +201223102180 email: [email protected] role: CONTACT email: [email protected] name: lamyaa E Allam, MD role: PRINCIPAL_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False |
<|newrecord|> nctId: NCT06260371 id: ORIGAMI briefTitle: National Observatory of Mycoplasma Infections in Children Under 18 Ages in France acronym: ORIGAMI overallStatus: RECRUITING date: 2023-09-01 date: 2030-09-01 date: 2030-09-01 date: 2024-02-15 date: 2024-02-15 name: Association Clinique Thérapeutique Infantile du val de Marne class: OTHER name: GPIP briefSummary: This study was set up because of an unusual increase in the number of cases of mycoplasma infections in France between June and November 2023. |
Clinical data from children with mycoplasma infections will be collected to characterise this infection and facilitate hospital management. conditions: Mycoplasma Infections conditions: Hospitalized Children studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 3000 type: ESTIMATED measure: Number of patients hospitalized for mycoplasma infections measure: medical characterisation of mycoplasma infections measure: Identify risk factors of serious infection measure: Identify predictive signs of serious infection measure: Type of complications measure: Patients outcome measure: healthcare used for infected children measure: treatment used during hospitalisation measure: clinical description of infected children measure: Type of mycoplasma involved in infected children measure: performance of complementary diagnostic tests for lung disorders measure: compare medical data collected during hospitalisation sex: ALL minimumAge: 1 Day maximumAge: 17 Years stdAges: CHILD facility: ACTIV status: RECRUITING city: Créteil zip: 94600 country: France name: Corinne Levy, MD role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] name: Stéphane Béchet, MSc role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] lat: 48.78333 lon: 2.46667 hasResults: False |
<|newrecord|> nctId: NCT06260358 id: 6043 briefTitle: Multidisciplinary Assesssment of Structured Report for Cervical Cancer Staging acronym: STRECC overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2025-03-31 date: 2024-02-15 date: 2024-02-15 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: This study aims to validate a structured report for cervical cancer anchored to the FIGO staging system. A structured report is hypothesized to aid in uniformly applying FIGO staging, reducing staging discrepancies and improving patient care and outcomes. |
Furthermore, we believe that the participation of the clinicians will improve the quality of the report to minimize the need for multidisciplinary team discussion conditions: Cervical Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Survey measure: Efficacy of a contextual structured report measure: Difference between satisfaction rate with narrative and structured report; measure: Comparison Single items response rate (for items 6 to 12 of the questionnaire related to clinical information), on both narrative and structured reports; measure: Differences in the single 6-to-12 items response rate between structured and narrative reports. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Advanced Radiology Center status: RECRUITING city: Rome zip: 00168 country: Italy name: Luca Russo role: CONTACT phone: +390630158637 email: [email protected] lat: 41.89193 lon: 12.51133 hasResults: False |
<|newrecord|> nctId: NCT06260345 id: CAPRICE briefTitle: CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit acronym: CAPRICE overallStatus: RECRUITING date: 2024-01-01 date: 2030-01-01 date: 2030-01-01 date: 2024-02-15 date: 2024-02-15 name: Association Clinique Thérapeutique Infantile du val de Marne class: OTHER name: GFRUP (Groupe Francophone de Réanimation et d'Urgences Pédiatrique) name: GPIP : Groupe de Pathologies Infectieuses Pédiatriques name: Centre National de Référence des Streptocoques name: Centre National de Référence des Pneumocoques name: Centre National de Référence des Méningocoques et Haemophilus influenzae name: Centre National de Référence des staphylocoques name: Centre National de Référence des E. Coli briefSummary: Severe bacterial infections are a worldwide scourge. However, the epidemiology of this type of infection varies over time. It is therefore essential to monitor them in order to prevent them more effectively. At this time, in France, no monitoring exists for this kind of infections. conditions: Hospitalized Children conditions: Severe Infection conditions: Invasive Bacterial Infection studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 3000 type: ESTIMATED measure: number of pediatrics cases of severe communautary bacterial infections measure: medical characterisation of children hospitalized for severe communautary bacterial infection case measure: Identify risk factors of serious infection measure: Identify predictive signs of severe cases in infected children. measure: healthcare used for infected children measure: Type of complications measure: Patients outcome measure: treatment used during hospitalisation measure: Bacterial strain characterization sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Association Clinique Thérapeutique Infantile du val de Marne status: RECRUITING city: Créteil zip: 94600 country: France name: Corinne Levy, MD role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] name: Stéphane Béchet, MsC role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] lat: 48.78333 lon: 2.46667 hasResults: False |
<|newrecord|> nctId: NCT06260332 id: INST UNM 2302 id: 23-293 type: OTHER domain: UNM HSC IRB briefTitle: Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors overallStatus: RECRUITING date: 2023-10-20 date: 2024-08-30 date: 2024-12-31 date: 2024-02-15 date: 2024-02-15 name: New Mexico Cancer Care Alliance class: OTHER name: University of New Mexico briefSummary: This clinical trial tests whether increased activity throughout the day can improve the chronic pain and associated symptoms that breast cancer survivors may experience after surgery. Staying active is a key factor of one's physical, mental, and social health and well-being. Moving more could also reduce pain and associated stress, anxiety, or depression. Using a fitness tracker may help patients to move around more, whether or not they choose to exercise. Information gathered from this study may help researchers learn how the use of a Fitbit tracker with health coaching may improve physical activity and reduce pain in young, Hispanic breast cancer survivors. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 25 type: ESTIMATED name: Supportive Care (Fitbit) measure: Recruitment rate (Feasibility) measure: Retention rate (Feasibility) measure: Adherence rate (Feasibility) measure: Incidence of adverse events measure: Change in chronic post-surgical pain measure: Change in physical activity measure: Change in health-related quality of life (hrQOL) sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: University of New Mexico Comprehensive Cancer Center status: RECRUITING city: Albuquerque state: New Mexico zip: 87106 country: United States name: Ellen R Wojcik, MBA-HCM role: CONTACT email: [email protected] name: Cheryl A Sampson, MBA role: CONTACT email: [email protected] name: Jacklyn M Nemunaitis, MD role: PRINCIPAL_INVESTIGATOR name: Cindy K Blair, Ph.D. role: SUB_INVESTIGATOR lat: 35.08449 lon: -106.65114 hasResults: False |
<|newrecord|> nctId: NCT06260319 id: C19-64 briefTitle: Decoding Developmental Disorders in Humams acronym: devodecode overallStatus: COMPLETED date: 2019-01-01 date: 2024-01-01 date: 2024-01-01 date: 2024-02-15 date: 2024-02-15 name: Institut National de la Santé Et de la Recherche Médicale, France class: OTHER_GOV name: Imagine Institute name: Commissariat A L'energie Atomique briefSummary: The DEVO-DECODE project aims to align our currently limited knowledge currently limited knowledge of the genetic architecture of developmental with our more advanced knowledge of their "phenome". |
To this end, we aim to establish a homogeneous cohort of patients with with developmental disorders to identify new genetic variants genetic variants, and thus study the association between developmental and genetic variants. Secondary objectives are:2 |
* Carry out WGS studies not only to refine exosomal sequencing data exome sequencing data, but above all to identify and validate non-coding non-coding DNA alterations, in both transcribed and non-transcribed transcribed or non-transcribed genomic domains |
* Develop precise preclinical models for functional studies of pathophysiological pathways conditions: Genetic Diseases studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 720 type: ACTUAL name: Whole genome sequencing and Genome-Epigenome-Phenome Associations measure: Primary objectives measure: secondary objectives 1 measure: secondary objectives 2 sex: ALL minimumAge: 1 Year maximumAge: 90 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Institut Imagine city: Paris zip: 75015 country: France lat: 48.85341 lon: 2.3488 hasResults: False |
<|newrecord|> nctId: NCT06260306 id: STUDY00002568 briefTitle: Hip Activation vs. Hip Activation + Core Stabilization overallStatus: COMPLETED date: 2024-01-24 date: 2024-04-12 date: 2024-04-12 date: 2024-02-15 date: 2024-04-26 name: Louisiana State University Health Sciences Center Shreveport class: OTHER briefSummary: The purpose of this investigation is to compare the effects of a combined hip activation and core stabilization training home exercise program (HEP) versus a hip activation training HEP alone on lower extremity (LE) frontal plane mechanics in healthy individuals. |
Specific Aim 1: To determine whether between- and/or within-group differences exist on the Forward Step-Down test (FSDT) when comparing a combined hip activation and core stabilization training HEP as compared to a hip activation training HEP. |
Specific Aim 2: To determine whether between- and/or within-group differences exist on the peak external knee abduction moment when comparing a combined hip activation and core stabilization training HEP to a hip activation training HEP. |
Specific Aim 3: To determine whether between- and/or within-group differences exist on gluteal and core muscle surface electromyography (sEMG) when comparing a combined hip activation and core stabilization training HEP to a hip activation training HEP. |
Specific Aim 4: To determine whether a dose-response relationship exists between HEP compliance and change on the FSDT, peak external knee abduction moment, and sEMG. conditions: Movement, Abnormal conditions: Lower Extremity Problem studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The PI who will be performing the data analysis will be blinded to participants' random group allocation. The other investigators who will be collecting the outcome data will know the group allocation. whoMasked: INVESTIGATOR count: 34 type: ACTUAL name: Hip activation home exercise program name: Hip activation plus core stabilization home exercise program measure: Forward Step Down Test (FSDT) measure: Maximal volitional isometric contraction (MVIC) via sensory electromyography (sEMG) of gluteus maximus (GMax) measure: Mean activation of GMax via sEMG measure: Peak activation of GMax via sEMG measure: MVIC via sEMG of gluteus medius (GMed) measure: Mean activation of GMed via sEMG measure: Peak activation of GMed via sEMG measure: MVIC via of transversus abdominis (TA) measure: Mean activation of TA via sEMG measure: Peak activation of TA via sEMG measure: Peak external knee abduction moment during drop landing task measure: Compliance with Home Exercise Program sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: LSU Health Sciences Center at Shreveport city: Shreveport state: Louisiana zip: 71103 country: United States lat: 32.52515 lon: -93.75018 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-07 uploadDate: 2024-01-18T21:23 filename: Prot_SAP_000.pdf size: 292995 hasResults: False |
<|newrecord|> nctId: NCT06260293 id: 4-2022-0208 briefTitle: The Effect of Post-operative Exercise in Gastric Cancer Patients: A Randomized Controlled Trial (RCT) Study overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-03 date: 2024-04-30 date: 2024-04-30 date: 2024-02-15 date: 2024-02-15 name: Yonsei University class: OTHER briefSummary: Medical advancements are enhancing the survival rates of individuals with gastric cancer. The growing population of gastric cancer survivors underscores the importance of managing treatment-related after-effects and side effects. Diminished physical function in cancer patients, particularly following gastric cancer surgery, is linked to increased mortality. The substantial decline in physical activity post-surgery contributes to a notable reduction in cardiorespiratory fitness and lower extremity muscle strength. Early postoperative exercise has demonstrated positive outcomes in colorectal cancer patients, facilitating early hospital discharge and supporting long-term recovery. However, there is a paucity of research on the efficacy of early postoperative exercise in the context of gastric cancer. Therefore, this study aims to evaluate the impact of early postoperative exercise on physical function following gastric cancer surgery. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 52 type: ACTUAL name: exercise measure: Shorts Physical Performance Battery(SPPB) sex: ALL minimumAge: 19 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Surgery, Yonsei University College of Medicine city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False |
<|newrecord|> nctId: NCT06260280 id: 4 briefTitle: Chronic Sleep Deprivation and Changes in Cortical and Hippocampal Volume overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2024-05-26 date: 2024-06-01 date: 2024-02-15 date: 2024-02-15 name: Instituto Mexicano del Seguro Social class: OTHER_GOV briefSummary: Sleep is a physiological state that is essential for human performance, including academic, occupational, interpersonal, and psychological aspects. Sleep disruption or deprivation leads to a loss of psychomotor skills and an increased association with various diseases. Therefore, it is critical to assess how chronic sleep deprivation affects medical residents who work long shifts, including those assigned during their training. conditions: Sleep Deprivation conditions: Hippocampal Atrophy conditions: Cortical Irregularity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 37 type: ESTIMATED name: Cerebral Nuclear Magnetic Resonance measure: Change in Hippocampal volumetry. measure: Change in cortical volumetry sex: ALL minimumAge: 24 Years maximumAge: 30 Years stdAges: ADULT facility: Unidad Medica de Alta Especialidad No. 1, Bajío city: Leon state: Guanajuato zip: 37260, country: Mexico lat: 21.12908 lon: -101.67374 hasResults: False |
<|newrecord|> nctId: NCT06260267 id: 000417 briefTitle: A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis overallStatus: RECRUITING date: 2024-03-12 date: 2025-09-15 date: 2025-09-15 date: 2024-02-15 date: 2024-04-05 name: Ferring Pharmaceuticals class: INDUSTRY briefSummary: To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC). conditions: Ulcerative Colitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 90 type: ESTIMATED name: Microbiota suspension name: Microbiota capsule name: Placebo suspension name: Placebo capsule measure: Treatment-emergent adverse events from baseline to week 52 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ferring Investigational Site status: RECRUITING city: North Little Rock state: Arkansas zip: 72117 country: United States name: Global Clinical Compliance role: CONTACT lat: 34.76954 lon: -92.26709 facility: Ferring Investigational Site status: RECRUITING city: Jacksonville state: Florida zip: 32256 country: United States name: Global Clinical Compliance role: CONTACT lat: 30.33218 lon: -81.65565 facility: Ferring Investigational Site status: RECRUITING city: Oklahoma City state: Oklahoma zip: 73102 country: United States name: Global Clinical Compliance role: CONTACT lat: 35.46756 lon: -97.51643 hasResults: False |
<|newrecord|> nctId: NCT06260254 id: 244826201 briefTitle: Effects of Railway Vibration on Sleep and Disease acronym: BioVib overallStatus: RECRUITING date: 2024-02-05 date: 2024-06-30 date: 2024-12-31 date: 2024-02-15 date: 2024-02-21 name: Göteborg University class: OTHER name: University of Pennsylvania name: University of Manitoba briefSummary: This study will investigate the biological mechanisms linking sleep disruption by vibration and noise, and the development of cardiometabolic disease. In a laboratory sleep study, the investigators will play railway vibration of different levels during the night. The investigators will also measure objective sleep quality and quantity, cognitive performance across multiple domains, self-reported sleep and wellbeing outcomes, and blood samples. Blood samples will be analyzed to identify metabolic changes and indicators of diabetes risk in different nights. Identifying biomarkers that are impacted by sleep fragmentation will establish the currently unclear pathways by which railway vibration exposure at night can lead to the development of diseases in the long term, especially metabolic disorders including diabetes. conditions: Noise Exposure conditions: Sleep Disturbance conditions: Sleep Hygiene conditions: Metabolic Disturbance conditions: Cognitive Change conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus) conditions: Vibration; Exposure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: All participants will be exposed to each of the different vibration conditions. Each study night is treated as a separate arm of the crossover study. The order of the vibration exposure conditions will be be randomly assigned across participants using a Latin square design to avoid first-order carryover effects. Each subject will be exposed to one night of each of the following: |
Quiet night: No noise or vibration will be played, serving as a control night to assess individual baseline sleep, metabolic profile, and cognitive performance; Three railway vibration nights to determine consequences of noise-disrupted sleep. The vibration level in these three nights will be 0.5 mm/s, 0.7 mm/s and 0.9 mm/s respectively, so that exposure-response relationships can be derived. primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: Participants will be aware that in any given study night they can be exposed to railway vibration and noise. They will not be informed what exposure condition will occur in any given night, but they can become unblinded to the exposure if they are awake, as they will may hear the noise or feel the vibration. |
Study investigators responsible for analysing cognitive performance variables and physiological sleep data will be be blind to which vibration and noise interventions were introduced on which study nights. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Railway noise name: Low level railway vibration name: Intermediate level railway vibration name: High level railway vibration measure: Fasting insulin resistance in the morning immediately after the Control night measure: Fasting insulin resistance in the morning immediately after the low vibration night measure: Fasting insulin resistance in the morning immediately after the intermediate vibration night measure: Fasting insulin resistance in the morning immediately after the high vibration night measure: Total sleep time during the Control night measure: Total sleep time during the low vibration night measure: Total sleep time during the intermediate vibration night measure: Total sleep time during the high vibration night measure: Total amount of N1 sleep during the Control night measure: Total amount of N2 sleep during the Control night measure: Total amount of N3 sleep during the Control night measure: Total amount of rapid eye movement (REM) sleep during the Control night measure: Total amount of N1 sleep during the low vibration night measure: Total amount of N2 sleep during the low vibration night measure: Total amount of N3 sleep during the low vibration night measure: Total amount of rapid eye movement (REM) sleep during the low vibration night measure: Total amount of N1 sleep during the intermediate vibration night measure: Total amount of N2 sleep during the intermediate vibration night measure: Total amount of N3 sleep during the intermediate vibration night measure: Total amount of rapid eye movement (REM) sleep during the intermediate vibration night measure: Total amount of N1 sleep during the high vibration night measure: Total amount of N2 sleep during the high vibration night measure: Total amount of N3 sleep during the high vibration night measure: Total amount of rapid eye movement (REM) sleep during the high vibration night measure: Wakefulness after sleep onset (WASO) during the Control night measure: Wakefulness after sleep onset (WASO) during the low vibration night measure: Wakefulness after sleep onset (WASO) during the intermediate night measure: Wakefulness after sleep onset (WASO) during the high vibration night measure: Number of awakenings during the Control night measure: Number of awakenings during exposure to low vibration measure: Number of awakenings during exposure to intermediate vibration measure: Number of awakenings during exposure to high vibration measure: Sleep onset latency (SOL) during the Control Night measure: Sleep onset latency (SOL) during the low vibration night measure: Sleep onset latency (SOL) during the intermediate vibration night measure: Sleep onset latency (SOL) during the high vibration night measure: Sleep efficiency during the Control night measure: Sleep efficiency during the low vibration night measure: Sleep efficiency during the intermediate vibration night measure: S Sleep efficiency during the high vibration night measure: Sleep depth assessed using the odds ratio product (ORP) during the Control night measure: Sleep depth assessed using the odds ratio product (ORP) during the low vibration night measure: Sleep depth assessed using the odds ratio product (ORP) during the intermediate vibration night measure: Sleep depth assessed using the odds ratio product (ORP) during the high vibration night measure: Maximal change of odds ratio product (ORP) during exposure to railway vibration events measure: Area under the curve of odds ratio product (ORP) during exposure to railway vibration events, calculated using the trapezoid rule measure: N-acetylglucosamine/galactosamine (GlycA) concentration after the Control night measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to low vibration night measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to intermediate vibration measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to high vibration measure: Sialic acid (GlycB) concentration after the Control night measure: Sialic acid (GlycB) concentration after exposure to low vibration measure: Sialic acid (GlycB) concentration after exposure to intermediate vibration measure: Sialic acid (GlycB) concentration after exposure to high vibration measure: Supramolecular phospholipid composite (SPC) concentration after the Control night measure: Supramolecular phospholipid composite (SPC) concentration after exposure to low vibration measure: Supramolecular phospholipid composite (SPC) concentration after exposure to intermediate vibration measure: Supramolecular phospholipid composite (SPC) concentration after exposure to high vibration measure: Ethanol concentration (mmol/L) after the Control night measure: Ethanol concentration (mmol/L) after exposure to low vibration night measure: Ethanol concentration (mmol/L) after exposure to intermediate vibration night measure: Ethanol concentration (mmol/L) after exposure to high vibration night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to Control night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to low vibration night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to intermediate vibration night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to high vibration night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to Control night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to low vibration night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to high vibration night measure: Alanine concentration (mmol/L) after exposure to Control night measure: Alanine concentration (mmol/L) after exposure to low vibration night measure: Alanine concentration (mmol/L) after exposure to intermediate vibration night measure: Alanine concentration (mmol/L) after exposure to high vibration night measure: Asparagine concentration (mmol/L) after exposure to Control night measure: Asparagine concentration (mmol/L) after exposure to low vibration night measure: Asparagine concentration (mmol/L) after exposure to intermediate vibration night measure: Asparagine concentration (mmol/L) after exposure to high vibration night measure: Creatine concentration (mmol/L) after exposure to Control night measure: Creatine concentration (mmol/L) after exposure to low vibration night measure: Creatine concentration (mmol/L) after exposure to intermediate vibration night measure: Creatine concentration (mmol/L) after exposure to high vibration night measure: Creatinine concentration (mmol/L) after exposure to Control night measure: Creatinine concentration (mmol/L) after exposure to low vibration night measure: Creatinine concentration (mmol/L) after exposure to intermediate vibration night measure: Creatinine concentration (mmol/L) after exposure to high vibration night measure: Glutamic acid concentration (mmol/L) after exposure to Control night measure: Glutamic acid concentration (mmol/L) after exposure to low vibration night measure: Glutamic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Glutamic acid concentration (mmol/L) after exposure to high vibration night measure: Glutamine concentration (mmol/L) after exposure to Control night measure: Glutamine concentration (mmol/L) after exposure to low vibration night measure: Glutamine concentration (mmol/L) after exposure to intermediate vibration night measure: Glutamine concentration (mmol/L) after exposure to high vibration night measure: Glycine concentration (mmol/L) after exposure to Control night measure: Glycine concentration (mmol/L) after exposure to low vibration night measure: Glycine concentration (mmol/L) after exposure to intermediate vibration night measure: Glycine concentration (mmol/L) after exposure to high vibration night measure: Histidine concentration (mmol/L) after exposure to Control night measure: Histidine concentration (mmol/L) after exposure to low vibration night measure: Histidine concentration (mmol/L) after exposure to intermediate vibration night measure: Histidine concentration (mmol/L) after exposure to high vibration night measure: Isoleucine concentration (mmol/L) after exposure to Control night measure: Isoleucine concentration (mmol/L) after exposure to low vibration night measure: Isoleucine concentration (mmol/L) after exposure to intermediate vibration night measure: Isoleucine concentration (mmol/L) after exposure to high vibration night measure: Leucine concentration (mmol/L) after exposure to Control night measure: Leucine concentration (mmol/L) after exposure to low vibration night measure: Leucine concentration (mmol/L) after exposure to intermediate vibration night measure: Leucine concentration (mmol/L) after exposure to high vibration night measure: Lysine concentration (mmol/L) after exposure to Control night measure: Lysine concentration (mmol/L) after exposure to low vibration night measure: Lysine concentration (mmol/L) after exposure to intermediate vibration night measure: Lysine concentration (mmol/L) after exposure to high vibration night measure: Methionine concentration (mmol/L) after exposure to Control night measure: Methionine concentration (mmol/L) after exposure to low vibration night measure: Methionine concentration (mmol/L) after exposure to intermediate vibration night measure: Methionine concentration (mmol/L) after exposure to high vibration night measure: N,N-Dimethylglycine concentration (mmol/L) after Control night measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to low vibration night measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to intermediate vibration night measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to high vibration night measure: Ornithine concentration (mmol/L) after exposure to Control night measure: Ornithine concentration (mmol/L) after exposure to low vibration night measure: Ornithine concentration (mmol/L) after exposure to intermediate vibration night measure: Ornithine concentration (mmol/L) after exposure to high vibration night measure: Phenylalanine concentration (mmol/L) after exposure to Control night measure: Phenylalanine concentration (mmol/L) after exposure to low vibration night measure: Phenylalanine concentration (mmol/L) after exposure to intermediate vibration night measure: Phenylalanine concentration (mmol/L) after exposure to high vibration night measure: Proline concentration (mmol/L) after exposure to Control night measure: Proline concentration (mmol/L) after exposure to low vibration night measure: Proline concentration (mmol/L) after exposure to intermediate vibration night measure: Proline concentration (mmol/L) after exposure to high vibration night measure: Sarcosine concentration (mmol/L) after exposure to Control night measure: Sarcosine concentration (mmol/L) after exposure to low vibration night measure: Sarcosine concentration (mmol/L) after exposure to intermediate vibration night measure: Sarcosine concentration (mmol/L) after exposure to high vibration night measure: Threonine concentration (mmol/L) after exposure to Control night measure: Threonine concentration (mmol/L) after exposure to low vibration night measure: Threonine concentration (mmol/L) after exposure to intermediate vibration night measure: Threonine concentration (mmol/L) after exposure to high vibration night measure: Tyrosine concentration (mmol/L) after exposure toControl night measure: Tyrosine concentration (mmol/L) after exposure to low vibration night measure: Tyrosine concentration (mmol/L) after exposure to intermediate vibration night measure: Tyrosine concentration (mmol/L) after exposure to high vibration night measure: Valine concentration (mmol/L) after Control night measure: Valine concentration (mmol/L) after exposure to low vibration night measure: Valine concentration (mmol/L) after exposure to intermediate vibration night measure: Valine concentration (mmol/L) after exposure to high vibration night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to Control night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to low vibration night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to high vibration night measure: Acetic acid concentration (mmol/L) after exposure to Control night measure: Acetic acid concentration (mmol/L) after exposure to low vibration night measure: Acetic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Acetic acid concentration (mmol/L) after exposure to high vibration night measure: Citric acid concentration (mmol/L) after Control night measure: Citric acid concentration (mmol/L) after exposure to low vibration night measure: Citric acid concentration (mmol/L) after exposure to intermediate vibration night measure: Citric acid concentration (mmol/L) after exposure to high vibration night measure: Formic acid concentration (mmol/L) after exposure to Control night measure: Formic acid concentration (mmol/L) after exposure to low vibration night measure: Formic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Formic acid concentration (mmol/L) after exposure to high vibration night measure: Lactic acid concentration (mmol/L) after exposure to Control night measure: Lactic acid concentration (mmol/L) after exposure to low vibration night measure: Lactic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Lactic acid concentration (mmol/L) after exposure to high vibration night measure: Succinic acid concentration (mmol/L) after exposure to Control night measure: Succinic acid concentration (mmol/L) after exposure to low vibration night measure: Succinic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Succinic acid concentration (mmol/L) after exposure to high vibration night measure: Choline concentration (mmol/L) after exposure to Control night measure: Choline concentration (mmol/L) after exposure to low vibration night measure: Choline concentration (mmol/L) after exposure to intermediate vibration night measure: Choline concentration (mmol/L) after exposure to high vibration night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to Control night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to low vibration night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to high vibration night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to Control night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to low vibration night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to high vibration night measure: Acetoacetic acid concentration (mmol/L) after exposure to Control night measure: Acetoacetic acid concentration (mmol/L) after exposure to low vibration night measure: Acetoacetic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Acetoacetic acid concentration (mmol/L) after exposure to high vibration night measure: Acetone concentration (mmol/L) after exposure to Control night measure: Acetone concentration (mmol/L) after exposure to low vibration night measure: Acetone concentration (mmol/L) after exposure to intermediate vibration night measure: Acetone concentration (mmol/L) after exposure to high vibration night measure: Pyruvic acid concentration (mmol/L) after exposure to Control night measure: Pyruvic acid concentration (mmol/L) after exposure to low vibration night measure: Pyruvic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Pyruvic acid concentration (mmol/L) after exposure to high vibration night measure: D-Galactose concentration (mmol/L) after exposure to Control night measure: D-Galactose concentration (mmol/L) after exposure to low vibration night measure: D-Galactose concentration (mmol/L) after exposure to intermediate vibration night measure: D-Galactose concentration (mmol/L) after exposure to high vibration night measure: Glucose concentration (mmol/L) after exposure to Control night measure: Glucose concentration (mmol/L) after exposure to low vibration night measure: Glucose concentration (mmol/L) after exposure to intermediate vibration night measure: Glucose concentration (mmol/L) after exposure to high vibration night measure: Glycerol concentration (mmol/L) after exposure to Control night measure: Glycerol concentration (mmol/L) after exposure to low vibration night measure: Glycerol concentration (mmol/L) after exposure to intermediate vibration night measure: Glycerol concentration (mmol/L) after exposure to high vibration night measure: Dimethylsulfone concentration (mmol/L) after exposure to Control night measure: Dimethylsulfone concentration (mmol/L) after exposure to low vibration night measure: Dimethylsulfone concentration (mmol/L) after exposure to intermediate vibration night measure: Dimethylsulfone concentration (mmol/L) after exposure to high vibration night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the control night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the low vibration night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the intermediate vibration night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the high vibration night measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the low vibration night measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the intermediate vibration night measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the high vibration night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the control night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the low vibration night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the intermediate vibration night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the high vibration night measure: Glucose tolerance in the morning after exposure to low vibration, assessed as glucose concentration 120 minutes after a glucose bolus measure: Glucose tolerance in the morning after exposure to intermediate vibration, assessed as glucose concentration 120 minutes after a glucose bolus measure: Glucose tolerance in the morning after exposure to high vibration, assessed as glucose concentration 120 minutes after a glucose bolus measure: Glucose tolerance in the morning after Control night, assessed as glucose concentration 120 minutes after a glucose bolus measure: Stumvoll Insulin sensitivity Index in the morning after control measure: Stumvoll Insulin sensitivity Index in the morning after exposure to low vibration measure: Stumvoll Insulin sensitivity Index in the morning after exposure to intermediate vibration measure: Stumvoll Insulin sensitivity Index in the morning after exposure to high vibration measure: Matsuda insulin sensitivity index in the morning after control exposure measure: Matsuda insulin sensitivity index in the morning after exposure to low vibration measure: Matsuda insulin sensitivity index in the morning after exposure to intermediate vibration measure: Matsuda insulin sensitivity index in the morning after exposure to high vibration measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to control measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to low vibration measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to intermediate vibration measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to high vibration measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to control measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to low vibration measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to intermediate vibration measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to high vibration measure: Self-reported sleep disturbance by vibration after control exposure measure: Self-reported sleep disturbance by vibration after exposure to low vibration measure: Self-reported sleep disturbance by vibration after exposure to intermediate vibration measure: Self-reported sleep disturbance by vibration after exposure to high vibration measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after control exposure measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after control exposure measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to control measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to control measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Event-related cardiovascular activation in response to control measure: Event-related cardiovascular activation in response to low vibration measure: Event-related cardiovascular activation in response to intermediate vibration measure: Event-related cardiovascular activation in response to high vibration measure: Evening neurobehavioural speed measure: Evening neurobehavioural accuracy sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: University of Gothenburg status: RECRUITING city: Gothenburg state: Västra Götaland zip: 42650 country: Sweden name: Michael G Smith, PhD role: CONTACT phone: +46317862843 email: [email protected] lat: 57.70716 lon: 11.96679 hasResults: False |
<|newrecord|> nctId: NCT06260241 id: ShaikhZayedH briefTitle: Gain in Stretched Penile Length After Phalloplasty With & Without Penile Traction in Children. overallStatus: RECRUITING date: 2023-01-01 date: 2025-01-01 date: 2025-01-01 date: 2024-02-15 date: 2024-02-15 name: Shaikh Zayed Hospital, Lahore class: OTHER briefSummary: The goal of this Randomized Controlled Trial is to assess the gain in stretched penile length after phalloplasty with \& without penile traction in children of age group 4 to 13 years presenting in hospital with the complaint of concealed penis. |
The main question\[s\] it aims to answer is: |
• Gain in stretched penile length after phalloplasty with and without penile traction in children. conditions: Concealed Penis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Control Trial primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 70 type: ESTIMATED name: Traction Dressing name: Without Traction Dressing measure: The gain in stretched penile length (SPL) sex: MALE minimumAge: 4 Years maximumAge: 13 Years stdAges: CHILD facility: Sheikh Zayed Hospital status: RECRUITING city: Lahore state: Punjab country: Pakistan name: ADEEL AHMED, MBBS MS role: CONTACT phone: 00923491467739 email: [email protected] lat: 31.558 lon: 74.35071 hasResults: False |
<|newrecord|> nctId: NCT06260228 id: STUDY02002270 briefTitle: HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's) acronym: HOBSCOTCH-PD overallStatus: RECRUITING date: 2024-01-05 date: 2024-08-01 date: 2024-11-30 date: 2024-02-15 date: 2024-02-15 name: Dartmouth-Hitchcock Medical Center class: OTHER briefSummary: The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Parkinson's Disease (PD) |
The main questions it aims to answer are: |
1. Can the current HOBSCOTCH program be adapted for people with PD? |
2. Will people with PD experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program? |
Participants will be asked to: |
* attend nine, one-hour virtual (online and/or by telephone) HOBSCOTCH-PD sessions with a one-on-one certified HOBSCOTCH-PD coach |
* complete a brief clinical questionnaire about their diagnosis of PD |
* complete two questionnaires before and after the HOBSCOTCH-PD sessions about their quality of life and about memory and thinking processes |
* keep a short daily diary about their PD symptoms and use of the self-management strategies taught in the HOBSCOTCH-PD program |
* complete a brief Satisfaction Survey after the entire HOBSCOTCH-PD program conditions: Parkinson Disease conditions: Cognitive Dysfunction conditions: Memory Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 5 type: ESTIMATED name: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) measure: Change in quality of life as measured by comparing PDQ-39 (Parkinson's Disease Questionnaire) scores pre- and post-HOBSCOTCH-PD intervention. measure: Change in subjective cognition as measured by comparing Neuro-QOL Item Bank v2.0 Cognitive Function scores pre- and post-HOBSCOTCH-PD intervention. sex: ALL minimumAge: 30 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dartmouth-Hitchcock status: RECRUITING city: Lebanon state: New Hampshire zip: 03756 country: United States name: Sarah J Kaden role: CONTACT phone: 603-540-5824 email: [email protected] lat: 43.64229 lon: -72.25176 hasResults: False |
<|newrecord|> nctId: NCT06260215 id: FFH briefTitle: Recovery Kinetics Following a Soccer Training in Middle-aged Males overallStatus: RECRUITING date: 2024-02-05 date: 2024-02-26 date: 2024-03-09 date: 2024-02-15 date: 2024-02-21 name: University of Thessaly class: OTHER briefSummary: This study aims at investigating the recovery kinetics of skeletal muscle damage, neuromuscular fatigue and performance following a single soccer trainning session in middle aged males. The participants will perform a soccer training session \[A single training session including 60 minutes of warm up, soccer technical exercises and small-sided game\] and a cotrol trial (No intervention included, only daily measurements) in randomized, repeated measures, crossover design. Assesesments related to skeletal muscle damage, performance and neuromuscular fatigue will be executed before the training session and daily for four consecutive days after training. conditions: Skeletal Muscle Damage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 11 type: ESTIMATED name: ST measure: Change in White blood cell count measure: Change in Granulocyte cell count measure: Change in Platelets cell count measure: Change in Monocyte cell count measure: Change in Lymphocyte cell count measure: Change in percentage of Hematocrit level measure: Change Red blood cells count measure: Change in Hemoglobin level measure: Change in Creatine kinase activity measure: Change in Total antioxidant capacity measure: Change in Glutathione concentration in blood measure: Change in countermovement jump height measure: Change in Peak power during coutermovement jump test measure: Change in isometric peak torque of knee extensors and flexors measure: Change in sprint time of 10 m measure: Change in sprint time of 30 m measure: Change in delayed onset of muscle soreness measure: Dietary intake measure: Peak Maximal oxygen consumption (Peak VO2) measure: Body Mass measure: Body Height measure: Body Fat measure: Lean body mass measure: Bone mass density measure: Bone mass content measure: Field activity during the soccer training measure: Heart rate during the soccer training measure: Systolic Blood Pressure measure: Dystolic Blood Pressure measure: Rest Heart Rate sex: MALE minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT facility: University o Thessaly, School of Physical Education and Sports Science status: RECRUITING city: Tríkala zip: 42100 country: Greece name: Athanasios Z Jamurtas, Prof role: CONTACT phone: +30 24310 47054 email: [email protected] name: Ioannis G Fatouros, Prof role: CONTACT phone: +30 24310 47047 email: [email protected] name: Athanasios S Poulios, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.55493 lon: 21.76837 hasResults: False |
<|newrecord|> nctId: NCT06260202 id: 308.273 briefTitle: Nutrition Under Noninvasive Ventilation acronym: NUTRINIV overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-05-31 date: 2024-05-31 date: 2024-02-15 date: 2024-02-16 name: Università degli Studi del Piemonte Orientale "Amedeo Avogadro" class: OTHER briefSummary: Even though nutrition is a fundamental component of Intensive care unit (ICU) therapy, critically ill patients are frequently malnourished, a factor well known for its strong association with a higher risk of complications, prolonged ICU/hospital length of stay, and greater ICU readmission and mortality rates. Noninvasive ventilation (NIV) use has increased considerably over the past twenty years, making this supportive technique a keystone of acute respiratory failure (ARF) treatment. In this setting, respiratory support is provided through an interface, usually a mask or a helmet, that frequently represents an important obstacle to nutrition delivery, making oral intake impossible and posing the necessity to start enteral (EN) or parenteral nutrition (PN). Moreover, while critical care guidelines regarding nutritional management of patients receiving mechanical ventilation (MV) are well established, data and recommendations about the appropriate nutritional support to patients in NIV are still very limited. Due to this limited data, we want to describe characteristics and nutritional management of patients undergoing NIV in ICU, and to evaluate the difference between the mean caloric and protein intake of these patients and the recommended caloric and protein target for critically ill patients. Secondarily, we want to evaluate the difference of the caloric and protein intake among groups of patients undergoing different nutritional modality and to assess potential associations of the nutritional characteristics with patient outcomes. conditions: Noninvasive Ventilation conditions: Nutrition Therapy conditions: Respiratory Insufficiency studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 112 type: ESTIMATED measure: Caloric and protein gap measure: Nutrition modalities outcomes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06260189 id: Soh-Med-24-01-02MD briefTitle: Assessment Of Serum And Tissue Levels Of Cold-Inducible RNA-Binding Protein In Patients With Lichen Planus overallStatus: RECRUITING date: 2024-02 date: 2025-02 date: 2025-10 date: 2024-02-15 date: 2024-02-15 name: Sohag University class: OTHER briefSummary: Lichen planus (LP) is a chronic inflammatory mucocutaneous disease of unknown etiology. |
Pathogenesis of LP is not completely understood, but it's considered a T-cell-mediated autoimmune disease. Cold-inducible RNA binding protein (CIRP or CIRBP) is a member of the glycine-rich RNA-binding protein family, Recent studies proved that CIRP acts as a tumor promoter through its actions on different cellular proliferation levels, Recently, the role of the damage associated molecular proteins and cytokines was highlighted in the pathogenesis of many disorders including psoriasis, alopecia areata, vitiligo, rheumatoid arthritis, other autoimmune diseases as well as several types of cancer. The aim of this study is to compare serum and tissue levels of CIRP in patients with LP and healthy controls. conditions: Assessment, Self studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 80 type: ESTIMATED measure: Assessment of cold-inducible RNA binding protein levels in serum and tissue sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Aya Ahmed Elsayed status: RECRUITING city: Sohag zip: 82511 country: Egypt name: Aya A Elsayed, Msc role: CONTACT phone: 00201060094631 phoneExt: Egypt email: [email protected] lat: 26.55695 lon: 31.69478 hasResults: False |
<|newrecord|> nctId: NCT06260176 id: 828722 id: R01DK113307 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK113307 id: 15163 type: REGISTRY domain: AsPredicted.org briefTitle: Vending Labeling Sales and Intercepts Study overallStatus: COMPLETED date: 2019-02-01 date: 2020-03-12 date: 2020-03-12 date: 2024-02-15 date: 2024-02-15 name: University of Pennsylvania class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The aim of this study is to compare the impact of 4 different types of front of package (FOP) food and beverage messages: 1) green labels on healthy foods, 2) red/yellow/green labels on less healthy/moderately healthy/healthy foods, 3) physical activity calorie equivalent labels, and 4) posters reminding consumers of the sweetened beverage tax on consumers' beverage and snack selections. conditions: Food Preferences conditions: Obesity conditions: Weight Gain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Machine locations were randomly assigned to 1 of 4 front-of-package message arms, stratified by baseline machine sales (high/low) and type of machine location (correctional facilities, courts/offices, large offices, police/fire, recreation centers/libraries/other) with equal probability. The investigators first randomized vending locations (e.g., floors) with beverage machines so that all machines on the same floor displayed the same label. They then randomized the remaining "solo" snack locations. Monthly sales data provided by the City's vending contractor indicated consumer choices. Research assistants also asked a subset of consumers (N=1,065) about their purchases. Intercepts were not allowed in the courts/offices location type and were not conducted at correctional facilities with low traffic. The aim was to collect 10 intercepts per machine visited, distributed over the entire study period, however the study was cut short in March 2020 by the Covid pandemic. primaryPurpose: PREVENTION masking: NONE count: 1065 type: ACTUAL name: exposure to healthy labels only name: exposure to healthiness information name: exposure to physical activity equivalents name: exposure to sweetened beverage tax messaging measure: Percentage of beverages sold with calories per month measure: Calories sold from beverages per month, if beverages with calories sold measure: Calories sold from snacks per month measure: Likelihood of selecting a healthy beverage measure: Likelihood of selecting a moderately healthy beverage measure: Likelihood of selecting a less healthy beverage measure: Likelihood of selecting a healthy snack measure: Likelihood of selecting a moderately healthy snack measure: Likelihood of selecting a less healthy snack measure: Total beverage units sold per month per machine. measure: Total snack units sold per month per machine measure: Total revenue per month per beverage machine measure: Total revenue per month per snack machine measure: Total calories sold per customer trip sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pennsylvania city: Philadelphia state: Pennsylvania zip: 19104 country: United States lat: 39.95233 lon: -75.16379 hasResults: False |
<|newrecord|> nctId: NCT06260163 id: CR109251 id: 2022-001285-35 type: EUDRACT_NUMBER id: CNTO1959PUC3001 type: OTHER domain: Janssen Research & Development, LLC id: 2022-502238-22-00 type: REGISTRY domain: EUCT number briefTitle: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis acronym: QUASAR Jr overallStatus: RECRUITING date: 2024-01-19 date: 2028-05-22 date: 2028-08-14 date: 2024-02-15 date: 2024-04-24 name: Janssen Research & Development, LLC class: INDUSTRY briefSummary: The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders. conditions: Colitis, Ulcerative studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 120 type: ESTIMATED name: Guselkumab Subcutaneous name: Matching Placebo name: Guselkumab Intravenous measure: Percentage of Participants with Clinical Remission at Week 56 measure: Percentage of Participants with Clinical Remission at Week 12 measure: Percentage of Participants With Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission at Week 12 measure: Percentage of Participants with Symptomatic Remission at Week 12 measure: United States: Percentage of Participants with Endoscopic Improvement at Week 12 measure: European Union: Percentage of Participants with Endoscopic Healing at Week 12 measure: Percentage of Participants with Clinical Response at Week 12 measure: Percentage of Participants with Symptomatic Remission at Week 56 measure: United States: Percentage of Participants With Endoscopic Improvement at Week 56 measure: European Union: Percentage of Participants With Endoscopic Healing at Week 56 measure: Percentage of Participants with Corticosteroid-free Clinical Remission at Week 56 measure: Percentage of Participants with Clinical Response at Week 56 measure: Percentage of Participants Histo-endoscopic Mucosal Improvement at Week 56 measure: Percentage of Participants with Symptomatic Remission at Week 56 Among Participants who had Symptomatic Remission at Week 12 measure: Percentage of Participants Who Achieve Endoscopic Normalization at Week 56 measure: Percentage of Participants With PUCAI Remission at Week 56 measure: Serum Concentration of Guselkumab During Induction Phase measure: Serum Concentration of Guselkumab During Maintenance Phase measure: Number of Participants with Incidence of Anti-guselkumab Antibodies measure: Percentage of Participants with Adverse Events (AEs) measure: Percentage of Participants with Serious Adverse Events (SAEs) measure: Percentage of Participants with AEs Leading to Discontinuation of Study Intervention sex: ALL minimumAge: 2 Years maximumAge: 17 Years stdAges: CHILD facility: Riley Hospital for Children status: RECRUITING city: Indianapolis state: Indiana zip: 46202 country: United States lat: 39.76838 lon: -86.15804 facility: UZ Gent status: RECRUITING city: Gent zip: 9000 country: Belgium lat: 51.05 lon: 3.71667 facility: UZ Brussel status: RECRUITING city: Jette zip: 1090 country: Belgium lat: 50.87309 lon: 4.33419 facility: Capital Institute of Pediatrics status: RECRUITING city: Beijing zip: 100020 country: China lat: 39.9075 lon: 116.39723 facility: Peking University Third Hospital status: RECRUITING city: Beijing zip: 100191 country: China lat: 39.9075 lon: 116.39723 facility: Changzhou No 2 Peoples Hospital status: RECRUITING city: Changzhou City zip: 213004 country: China facility: The Childrens Hospital Zhejiang University School Of Medicine status: RECRUITING city: Hangzhou zip: 310005 country: China lat: 30.29365 lon: 120.16142 facility: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine status: RECRUITING city: Hangzhou zip: 310016 country: China lat: 30.29365 lon: 120.16142 facility: Ruijin Hospital, Shanghai Jiao Tong University status: RECRUITING city: Shanghai zip: 200025 country: China lat: 31.22222 lon: 121.45806 facility: Shengjing Hospital of China Medical University status: RECRUITING city: Shenyang zip: 110004 country: China lat: 41.79222 lon: 123.43278 facility: Hvidovre Hospital status: RECRUITING city: Hvidovre zip: 2650 country: Denmark lat: 55.65719 lon: 12.47364 facility: AOU Policlinico Umberto I status: RECRUITING city: Roma zip: 00161 country: Italy lat: 41.89193 lon: 12.51133 facility: Kanazawa University Hospital status: RECRUITING city: Kanazawa zip: 920-8641 country: Japan lat: 36.6 lon: 136.61667 facility: Kobe University Hospital status: RECRUITING city: Kobe zip: 650-0017 country: Japan lat: 34.6913 lon: 135.183 facility: Japanese Red Cross Kumamoto Hospital status: RECRUITING city: Kumamoto zip: 861-8520 country: Japan lat: 32.80589 lon: 130.69182 facility: Shinshu University Hospital status: RECRUITING city: Matsumoto zip: 390-8621 country: Japan lat: 36.23333 lon: 137.96667 facility: Saga University Hospital status: RECRUITING city: Saga zip: 849-8501 country: Japan lat: 33.23333 lon: 130.3 facility: Tokyo Medical University Hospital status: RECRUITING city: Shinjuku zip: 160-0023 country: Japan lat: 35.2946 lon: 139.57059 facility: Osaka Medical and Pharmaceutical University Hospital status: RECRUITING city: Takatsuki zip: 569-8686 country: Japan lat: 34.84833 lon: 135.61678 facility: Saiseikai Yokohamashi Tobu Hospital status: RECRUITING city: Yokohama zip: 230-8765 country: Japan lat: 35.43333 lon: 139.65 facility: Korczowski Bartosz Gabinet Lekarski status: RECRUITING city: Rzeszow zip: 35-302 country: Poland lat: 50.04132 lon: 21.99901 facility: Medical Network Spolka z o.o. WIP Warsaw IBD Point Profesor Kierkus status: RECRUITING city: Warszawa zip: 04 501 country: Poland lat: 52.22977 lon: 21.01178 facility: Instytut Pomnik Centrum Zdrowia Dziecka status: RECRUITING city: Warszawa zip: 04 730 country: Poland lat: 52.22977 lon: 21.01178 facility: Gazi University Medical Faculty status: RECRUITING city: Ankara zip: 06560 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06260150 id: ZXT briefTitle: Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients. overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-01 date: 2024-04 date: 2024-04 date: 2024-02-15 date: 2024-02-15 name: Feng Tian class: OTHER_GOV briefSummary: The goal of this clinical trial is to evaluate the effectiveness of intraoperative intermittent pneumatic compression (IPC) device usage in preventing lower extremity deep vein thrombosis (DVT) in patients undergoing gastrointestinal surgery.The main question it aims to answer is provide a reference basis for determining the efficacy of IPC application during gastrointestinal surgery for preventing lower extremity DVT in patients. |
Participants are patients who require gastrointestinal surgery, specifically for the resection of gastrointestinal tumors. They will be divided into a control group and an experimental group. The experimental group will use an Intermittent Pneumatic Compression (IPC) device during surgery, while the control group will receive standard treatment. The objective is to observe whether the use of IPC during surgery can prevent the formation of Deep Vein Thrombosis (DVT) or lower the Risk of DVT. conditions: Gastrointestinal Neoplasms conditions: Stomach Neoplasms conditions: Intestinal Neoplasms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Intermittent Pneumatic Compression Devices measure: Incidence rate of DVT measure: Length of surgery measure: Intraoperative body temperature measure: Amount of bleeding during surgery sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shandong Provincial Hospital city: Jinan state: Shandong zip: 250021 country: China lat: 36.66833 lon: 116.99722 hasResults: False |
<|newrecord|> nctId: NCT06260137 id: UludagThorax briefTitle: Comparison of Two Different Methods for Reducing Pain After Lung Surgery overallStatus: ACTIVE_NOT_RECRUITING date: 2023-07-10 date: 2024-07 date: 2024-08 date: 2024-02-15 date: 2024-02-15 name: Uludag University class: OTHER briefSummary: The goal of this clinical study is to compare the effectiveness of the Rhomboid Intercostal Block and Sub-Servitus plan block and the effectiveness of the Rhomboid intercostal block in patients with video-supported thoracoscopic surgery. The main question it aims to answer is: |
Which of these two blocks more effectively reduces the patients' pain? conditions: Postoperative Analgesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Rhomboid intercostal block name: Rhomboid intercostal and subserratus plane block measure: Postoperative analgesia sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hastane city: Bursa zip: 16210 country: Turkey lat: 40.19559 lon: 29.06013 hasResults: False |
<|newrecord|> nctId: NCT06260124 id: Greek Dancing-UTH briefTitle: Acute Physiological Effects of Greek Traditional Dancing overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-06-30 date: 2024-10-30 date: 2024-02-15 date: 2024-04-09 name: University of Thessaly class: OTHER briefSummary: In Greece, people of different age groups, including young children to older adults, are involved in traditional dance. To date, the well-know benefits of dancing include entertainment, socialization and increased physical activity. However, the acute effects of Greek traditional dancing on health, physical performance and muscle damage indices remain largely unknown. Therefore, the aim of this project is to evaluate the acute effect of Greek traditional dancing on health-, physical performance-, and muscle damage-related parameters by considering the impact of dancing tempo (slow vs moderate vs fast). In a crossover repeated measures design 10 pre- and 10 post-menopausal women will participate in the three dancing sessions of different tempo in a random order. conditions: Menopause conditions: Cardiovascular Health conditions: Body Composition conditions: Physical Performance conditions: Muscle Damage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 20 type: ESTIMATED name: Slow tempo name: Moderate tempo name: Fast tempo measure: Change in blood pressure measure: Change in perceived exertion measure: Change in blood lactate measure: Change in resting metabolic rate measure: Change in delayed-onset of muscle soreness (DOMS) measure: Change in maximal isometric voluntary contraction measure: Change in joint range of motion measure: Change in functional performance measure: Change in white blood cell count measure: Change in granulocyte count measure: Change in lymphocytes measure: Change in monocytes measure: Change in creatine kinase concentration measure: Change in reduced glutathione measure: Change in oxidized glutathione measure: Change in catalase activity measure: Change in protein carbonyls measure: Change in total antioxidant capacity measure: Change in heart rate measure: Change in oxygen consumption measure: Change in physical activity measure: Change in red blood cell count measure: Change in hematocrit measure: Change in hemoglobin sex: FEMALE minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06260111 id: SA23I0021 briefTitle: Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation acronym: POMFITT overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2025-10-30 date: 2025-10-30 date: 2024-02-15 date: 2024-02-15 name: Universidad del Desarrollo class: OTHER name: Agencia Nacional de Investigación y Desarrollo name: Clínica Dávila briefSummary: The goal of this clinical trial is to test the efficacy of laser photobiomodulation in adult hematologic cancer patients undergoing hematopoietic stem cell transplantation (HSCT). The main questions it aims to answer are: • Is photobiomodulation with laser in the oral cavity, compared to standard care, effective in preventing oral mucositis and functional impairments in adult patients receiving HSCT? • What is the level of patient´s acceptability of photobiomodulation with laser in the oral cavity during HSCT? Participants once a day will receive photobiomodulation (diode laser device) in their oral cavity from the first day of transplantation conditioning until third day post-transplant. Researchers will compare with usual care to see if photobiomodulation helps preventing oral mucositis and functional impairment. conditions: Hematologic Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The design of the study consists of a randomized, controlled trial with parallel groups (photobiomodulation + usual care versus a control group with only usual care), allocation ratio of 1:1. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Assessor will be blinded only for the secondary outcomes. The person responsible for statistical analyses will also be blinded. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Photobiomodulation name: Usual care measure: Oral Mucositis measure: Level of Pain measure: Handgrip strength measure: Exercise tolerance measure: Physical fitness measure: Health related quality of life measure: Length of hospital stay measure: Use of opioids measure: Body mass index measure: Nutritional status measure: Daily calorie intake measure: Arm circumference measure: Triceps skinfold sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinica Dávila city: Santiago state: Metropolitana zip: 8431657 country: Chile name: Tomás A López-Espinoza, MSc.C. role: CONTACT phone: +56962056755 email: [email protected] name: Hernán López, MD role: CONTACT phone: +56966795985 email: [email protected] name: Monica Peña, Nurse role: SUB_INVESTIGATOR lat: -33.45694 lon: -70.64827 hasResults: False |
<|newrecord|> nctId: NCT06260098 id: H23-0617 briefTitle: StressLess Yoga Study overallStatus: RECRUITING date: 2024-04-03 date: 2024-05-30 date: 2024-05-30 date: 2024-02-15 date: 2024-04-05 name: University of Connecticut class: OTHER briefSummary: The purpose of this study is to assess the feasibility and acceptability of using an asynchronous online yoga program to reduce stress. The study will use an 8 week asynchronous yoga intervention of two different types of yoga (high in breath work and meditation; low in vigorous movement/postures vs. low breath work and meditation; high movement/postures). In addition to self-report stress, measures include sleep, heart rate variability, mindfulness, Essential Properties of Yoga, and acceptability questions. conditions: Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Yoga with High Breath work & meditation; Low movement/postures name: Yoga with Low Breath work & meditation; High movement/postures measure: The number (percentage)of people completing the whole protocol (6/8 yoga classes & 2 in-person visits) measure: The combined score (out of 35) on the 5-item Treatment Acceptability Questionnaire (TAQ) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bousfield Psychology Building, 406 Babbidge Road status: RECRUITING city: Storrs state: Connecticut zip: 06269 country: United States name: Crystal Park, PhD role: CONTACT phone: 860-486-3520 email: [email protected] name: Crystal Park, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.80843 lon: -72.24952 hasResults: False |
<|newrecord|> nctId: NCT06260085 id: 686 briefTitle: Effect of Listening to Relatives' Voice Recordings on Chest Pain, Anxiety, and Depression in Coronary ICU Patients overallStatus: COMPLETED date: 2022-06-04 date: 2023-07-04 date: 2023-09-04 date: 2024-02-15 date: 2024-02-15 name: T.C. ORDU ÜNİVERSİTESİ class: OTHER briefSummary: The aim of the study was to evaluate the effect of listening to the voice recordings of relatives of patients with acute myocardial infarction (AMI) who were treated in the coronary intensive care unit on chest pain, anxiety and depression parameters of the patients. |
Methods In the study, which was conducted as a randomised, controlled, experimental study, voice recordings of the family members of the patients were created and played to the patients through a music pillow. The study was carried out with 60 patients, 30 experimental and 30 control groups. Three tests were applied to the patients 15 minutes before, 15 and 30 minutes after the application. The data of the study were collected using the "Patient Introduction Form", "Hospital Anxiety Depression Scale", "Visual Analogue Scale" and "Patient Follow-up Form". conditions: Acute Myocardial Infarction conditions: Intensive Care Unit Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The clinical nurse collected the data whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Relatives vioce record measure: Chest Pain measure: Anxiety, and Depression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yasemin Kalkan Uğurlu city: Ordu zip: 52200 country: Turkey lat: 40.97782 lon: 37.89047 hasResults: False |
<|newrecord|> nctId: NCT06260072 id: IRB-HSR 21920 briefTitle: Magnesium and Riboflavin Treatment for Post-Concussion Headache overallStatus: RECRUITING date: 2020-02-10 date: 2024-12-31 date: 2024-12-31 date: 2024-02-15 date: 2024-02-16 name: University of Virginia class: OTHER briefSummary: This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person. conditions: Concussion, Intermediate studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 108 type: ESTIMATED name: magnesium and riboflavin supplement measure: Headache Intensity and Duration sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Virginia Student Health and Wellness Center status: RECRUITING city: Charlottesville state: Virginia zip: 22903 country: United States name: Karen Ahern, BSN MBA role: CONTACT phone: 434-924-1549 email: [email protected] lat: 38.02931 lon: -78.47668 hasResults: False |
<|newrecord|> nctId: NCT06260059 id: STUDY23070148 id: Pitt2024 type: OTHER_GRANT domain: Pittsburgh Foundation briefTitle: Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease acronym: EmpaCHD overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2026-12-31 date: 2027-06-01 date: 2024-02-15 date: 2024-02-15 name: Anita Saraf class: OTHER name: The Pittsburgh Foundation briefSummary: The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD). conditions: Adult Congenital Heart Disease conditions: Heart Failure studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Group 1: Empagliflozin 10 MG daily Group 2: Placebo primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Empagliflozin 10 MG name: Placebo measure: Change in Ejection fraction (EF) measure: Change in Myocardial characteristics (T1 mapping of cMRI) measure: Change in Myocardial characteristics (Global strain on MRI) measure: Change in Myocardial characteristics (Global strain on echocardiogram) measure: Change in functional exercise capacity of participants. measure: Number of Participants Hospitalized for Cardiac Reasons or heart transplantation measure: Number of Deaths measure: Change in inflammatory serum biomarkers measure: Change in functional Neuropsychological Testing measure: Change in New York Heart Association (NYHA) Class measure: Change Patient-Reported Outcomes Measurement Information System (PROMIS) measure: Change in Kansas City Cardiomyopathy (KCCQ) measure: Change in Neuro-QOL sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Magee Women's Hospital city: Pittsburgh state: Pennsylvania zip: 15213 country: United States lat: 40.44062 lon: -79.99589 facility: Presbyterian Hospital city: Pittsburgh state: Pennsylvania zip: 15213 country: United States lat: 40.44062 lon: -79.99589 facility: Children's Hospital of Pittsburgh city: Pittsburgh state: Pennsylvania zip: 15224 country: United States lat: 40.44062 lon: -79.99589 hasResults: False |
<|newrecord|> nctId: NCT06260046 id: Robot Nx-SFTN briefTitle: Effect of Sufentanil on the Postoperative Pain overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-01-15 date: 2027-01-15 date: 2024-02-15 date: 2024-02-15 name: Seoul National University Hospital class: OTHER briefSummary: This study is a randomized, controlled trial. A total of 48 patients will be randomized to receive sufentanil or remifentanil during robot-assisted nephrectomy surgery. conditions: Postoperative Pain, Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: Sufentanil name: Remifentanil measure: opioid consumption measure: Richmond Agitation-Sedation scale measure: Incidence of postoperative nausea and vomiting measure: Number of patients who administered antiemetics measure: Pain score sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Bundang Hospital city: Seongnam country: Korea, Republic of name: Chang-Hoon Koo role: CONTACT email: [email protected] lat: 37.43861 lon: 127.13778 hasResults: False |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.